Skip to contentpdufa.bio

DURAVYU (vorolanib intravitreal insert, EYP-1901)

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

DURAVYU (vorolanib intravitreal insert, EYP-1901) is an EyePoint, Inc. program in diabetic macular edema. Its next catalyst is a Readout in Q4 2027.

EYPT catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indication under review: Diabetic macular edema. Sponsor: EyePoint, Inc. (EYPT). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Q4 2027EYPT

Specialist biotech funds holding EYPT, 13F for the quarter ended September 30, 2026

FundSharesValue at quarter endFiling
Cormorant Asset Management5,750,000$18.8 millionfiled November 16, 2026
OrbiMed Advisors739,691$2.4 millionfiled November 16, 2026

13F reports list long positions in common stock at quarter end, are due 45 days later, and show no short positions or later trades. Notes, warrants and other instruments are not counted as shares.

Questions

When is DURAVYU (vorolanib intravitreal insert, EYP-1901)'s next FDA decision or readout?

The next tracked catalyst for DURAVYU (vorolanib intravitreal insert, EYP-1901) is a Readout in Q4 2027.

What happened at DURAVYU (vorolanib intravitreal insert, EYP-1901)'s most recent FDA decision?

No FDA decision for DURAVYU (vorolanib intravitreal insert, EYP-1901) is in our archive yet.

What is DURAVYU (vorolanib intravitreal insert, EYP-1901) used for?

In our records DURAVYU (vorolanib intravitreal insert, EYP-1901) is under review or in development for Diabetic macular edema.

Who makes DURAVYU (vorolanib intravitreal insert, EYP-1901)?

EyePoint, Inc. (EYPT).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.